Compare BioNTech SE - ADR (BNTX) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs ProShares UltraPro QQQ ETF — how do they compare? BioNTech SE - ADR trades at $89.8 (market cap $22.86B), while ProShares UltraPro QQQ ETF trades at $75.09. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | TQQQ | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $119.34 | $87.22 |
52-Week Low | $83.89 | $37.89 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $72.64, down 5.7% in the last 24 hours amid a bearish technical signal. The fund lacks traditional financial ratios as it is not a company, and recent news highlights concerns over volatility amplification and hidden costs. Support is seen at $72, with resistance at $74.
Outlook is cautious due to leveraged structure magnifying losses in downturns; opportunities exist for tactical traders during tech rallies, but risks include daily rebalancing decay and market volatility. Long-term holders face significant drawdown risks, as seen in 2022's 81% drop versus Nasdaq's 33% decline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
